ArticleFrontiers in cardiovascular medicine2025
Secretoneurin plasma levels are decreased after catheter ablation for atrial fibrillation-patients with AF produce lower SN levels than healthy individuals: the SAFE registry.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05794464 (Secretoneurin as a Biomarker of Atrial Fibrillation rEcurrence After Catheter Ablation/Electrical Cardioversion), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Secretoneurin as a Biomarker of Atrial Fibrillation rEcurrence After Catheter Ablation/Electrical Cardioversion
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Secretoneurin (SN) is a neuropeptide that counterbalances disorders of cell calcium cycling via calmodulin and thus may be involved in arrhythmogenesis. We aimed to associate plasma standard biomarkers and SN levels before, during, and after catheter ablation for atrial fibrillation (AF) with various clinical and paraclinical variables, foremost AF recurrence. Methods: We prospectively enrolled consecutive patients undergoing catheter ablation for AF in University Hospital Ostrava between March 2023 and January 2024. SN was analyzed from venous, left atrial, and coronary sinus blood with the ELISA method. Plasma SN levels were compared before, during, and after ablation and with those of healthy individuals, with nonparametric tests. ClinicalTrials.gov ID: NCT05794464. Results: A total of 137 patients (64% males, age 63 ± 11) and 34 healthy individuals (38% males, mean age 31 ± 7.1) were included in the analysis. Plasma SN levels were significantly lower after the catheter ablation as compared with SN levels before (34.0 ± 15.1 and 40.0 ± 17.3 pmol/L, Conclusion: Plasma secretoneurin levels are decreased after catheter ablation for atrial fibrillation; patients with AF produce lower SN levels than healthy individuals. Lower postprocedural levels of SN are associated with AF recurrences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.